Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection
News
The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas ... Read more